These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10575269)

  • 1. The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer.
    Al Khalifa M; Elfving P; Månsson W; Colleen S; Hellsten S; Duchek M; Nyberg G; Callaghan P; Rademark C; Eriksson R; Olsson R; Hagberg G; Nelson CE
    Eur Urol; 2000; 37 Suppl 1():26-30. PubMed ID: 10575269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911.
    Vegt PD; van der Meijden AP; Sylvester R; Brausi M; Höltl W; de Balincourt C
    J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
    Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical experience with BCG immune prevention in superficial bladder cancer].
    Bach D; Romics I; Rüssel C
    Urologe A; 1992 Sep; 31(5):296-301. PubMed ID: 1302409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal BCG treatment of superficial bladder cancer as defined by American trials.
    Lamm DL
    Eur Urol; 1992; 21 Suppl 2():12-6. PubMed ID: 1396941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder.
    Akaza H; Koiso K; Ozono S; Kuroda M; Kameyama S; Okajima E; Kotake T; Kakizoe T; Kawabe K;
    Jpn J Clin Oncol; 2003 Aug; 33(8):382-90. PubMed ID: 14523057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
    Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
    Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose bacille Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada.
    Mack D; Frick J
    Br J Urol; 1995 Feb; 75(2):185-7. PubMed ID: 7850323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical BCG therapy of superficial bladder cancer: study of adverse effects.
    Galván L; Ayani I; Arrizabalaga MJ; Rodriguez-Sasiain JM
    J Clin Pharm Ther; 1994 Apr; 19(2):101-4. PubMed ID: 8071388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.
    Witjes JA; vd Meijden AP; Witjes WP; Doesburg W; Schaafsma HE; Debruyne FM
    Eur J Cancer; 1993; 29A(12):1672-6. PubMed ID: 8398292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment.
    Yates J; Stein B
    Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Miliary pneumonia after the intravesical BCG therapy of a superficial urothelial carcinoma of the bladder].
    Habscheid W; Feise F; Dahm HH
    Dtsch Med Wochenschr; 1999 Aug; 124(34-35):993-7. PubMed ID: 10488326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment.
    Paterson DL; Patel A
    Aust N Z J Surg; 1998 May; 68(5):340-4. PubMed ID: 9631906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified induction course: a solution to side-effects?
    Bassi P; Spinadin R; Carando R; Balta G; Pagano F
    Eur Urol; 2000; 37 Suppl 1():31-2. PubMed ID: 10575270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical approaches to the prevention and treatment of adverse reactions to BCG.
    van der Meijden AP
    Eur Urol; 1995; 27 Suppl 1():23-8. PubMed ID: 7750529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.